GlassScriptPhysician profile
Charles L Huh
NPI 1255379889
$8,203.20
in general payments reported to CMS, 2019-2025
30 companies · $1,308 in 2025
The $1,308 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,189 · 2020: $447 · 2021: $1,468 · 2022: $1,532 · 2023: $1,437 · 2024: $823 · 2025: $1,308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,464 · Gift: $81.81 · Education: $21.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,464.09 |
| Gift | $81.81 |
| Education | $21.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,637.25 | 2019-2025 | |
| Gilead Sciences, INC. | $1,089.65 | 2019-2025 | Livdelzi |
| Takeda Pharmaceuticals U.S.A., INC. | $922.48 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $785.52 | 2019-2025 | Xifaxan, Trulance |
| Braintree Laboratories, INC. | $761.15 | 2019-2023 | Suflave, Sutab |
| Celgene Corporation | $708.92 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $404.95 | 2019-2025 | Stelara, Remicade, Simponi Aria |
| Qol Medical, LLC | $350.96 | 2019-2025 | Sucraid |
| Pfizer INC. | $250.99 | 2019-2025 | |
| Ardelyx, INC. | $191.71 | 2022-2025 | Ibsrela |
| Genzyme Corporation | $137.83 | 2022-2023 | |
| Phathom Pharmaceuticals, INC. | $129.88 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $118.67 | 2019-2024 | Ocaliva |
| Ferring Pharmaceuticals INC. | $108.62 | 2019-2023 | Rebyota |
| Covidien LP | $97.67 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $93.80 | 2025 | Omvoh |
| Madrigal Pharmaceuticals | $70.22 | 2024-2025 | Rezdiffra, Resmetirom |
| Nestle Healthcare Nutrition INC. | $61.33 | 2021-2023 | |
| Redhill Biopharma INC. | $49.62 | 2021-2023 | Talicia |
| Ironwood Pharmaceuticals, INC | $45.08 | 2020-2021 | |
| Mylan Specialty L.P. | $27.78 | 2023 | Yupelri |
| Ipsen Biopharmaceuticals, INC | $25.39 | 2025 | Iqirvo |
| Celltrion USA INC. | $21.82 | 2024 | Zymfentra |
| Vivus LLC | $20.77 | 2025 | Qsymia |
| Boston Scientific Corporation | $17.57 | 2024 | Cre Pro |
| Regeneron Healthcare Solutions, INC. | $16.57 | 2023 | Dupixent |
| Aimmune Therapeutics, INC. | $15.92 | 2025 | Zenpep |
| Merck Sharp & Dohme LLC | $14.01 | 2020 | |
| Alfasigma USA, INC. | $13.60 | 2020 | |
| Olympus America INC. | $13.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Huh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.